In normal cells and the early stages of cancer, TGF-β restrains cell proliferation whereas, in advanced stages of cancer, due to accumulation of mutations in the TGF-β pathway components or selective impairment of its tumour-suppressive function, it turns out to be oncogenic [24,25,26]. The gene discussed is TGFB1; the disease is cancer.